Keyphrases
Periprosthetic Joint Infection
100%
Infective Endocarditis
57%
Spain
52%
Implant Retention
40%
Debridement
35%
HIV Patients
31%
Infectious Diseases
31%
Multicenter Cohort Study
29%
Odds Ratio
28%
Clinical Microbiology
28%
COVID-19
27%
Clinical Outcomes
26%
Staphylococcus Aureus
26%
Solid Organ Transplant Recipients
25%
Tuberculosis
24%
Antibiotics
24%
Hospitalized Patients
22%
Confidence Interval
21%
Healthcare-associated
21%
Spanish Society
20%
Etiology
20%
Comorbidity
20%
Bacterial Meningitis
19%
Pneumocystis Jirovecii
19%
Colistin
18%
Antibiogram
18%
Pseudomonas Aeruginosa (P. aeruginosa)
18%
Epidemiology
18%
Bacteremia
18%
Rifampin
17%
Pseudomonas Aeruginosa Bacteraemia
17%
Methicillin-resistant Staphylococcus Aureus
17%
Matched Cohort Study
17%
Endocarditis
17%
Fever
16%
Extensively Drug-resistant
16%
Urinary Tract Infection
16%
Prospective Cohort Study
16%
Risk Factors
15%
Adult Patients
15%
Barcelona
14%
Elderly Patients
14%
Multidrug-resistant
13%
Pulmonary Infiltrates
13%
Joint Infection
13%
Monotherapy
13%
Microorganisms
12%
Late Acute
12%
Executive Summary
12%
Multidrug-resistant Pseudomonas Aeruginosa (MDRPA)
12%
Medicine and Dentistry
Infection
87%
Prosthetics
64%
Infectious Arthritis
64%
Infective Endocarditis
58%
Endocarditis
46%
Human Immunodeficiency Virus
37%
Cohort Analysis
31%
Bloodstream Infection
29%
Staphylococcus Aureus
27%
Debridement
26%
Pseudomonas aeruginosa
24%
Implant
24%
Antibiotics
22%
Odds Ratio
21%
Antibiogram
21%
COVID-19
21%
Antibiotic Therapy
19%
Bacterial Meningitis
17%
Antiinfective Agent
16%
Prospective Cohort Study
15%
Retrospective Study
15%
Observational Study
14%
Pulmonary Infiltrate
13%
Comorbidity
13%
Prevalence
13%
Antiretroviral Therapy
12%
Periprosthetic Joint Infection
12%
Septic Arthritis
12%
Cohort Effect
12%
Transplantation
12%
Surgery
11%
Highly Active Antiretroviral Therapy
11%
Antibiotic Resistance
11%
Gram-Negative Bacteria
11%
Arthroplasty
10%
Prosthesis
10%
Immunocompromised Patient
9%
Clinical Feature
9%
Health Care
9%
Diseases
9%
Systematic Review
9%
Sepsis
9%
Rifampicin
9%
In Vitro
9%
Methicillin Resistant Staphylococcus Aureus
8%
Hospital Mortality
8%
Interleukin 6
8%
Mortality Rate
8%
Elderly Patient
8%
Population
8%
Pharmacology, Toxicology and Pharmaceutical Science
Infection
75%
Infectious Arthritis
56%
Bloodstream Infection
34%
Endocarditis
33%
Cohort Study
32%
Pseudomonas aeruginosa
27%
Bacterial Endocarditis
24%
Disease
23%
Rifampicin
23%
Antibiotics
23%
Staphylococcus Aureus
23%
Implant
21%
Prospective Cohort Study
19%
Bacterial Meningitis
19%
Mortality Rate
15%
Comorbidity
15%
Coronavirinae
14%
Retrospective Study
13%
Monotherapy
13%
Methicillin-Resistant Staphylococcus Aureus
13%
Antibiotic Therapy
13%
Colistimethate
12%
Nephrotoxicity
11%
Prevalence
10%
Adverse Event
10%
Observational Study
9%
Clinical Feature
9%
Microorganism
9%
Interleukin 6
9%
SARS Coronavirus
9%
Tuberculosis
9%
Combination Therapy
9%
Periprosthetic Joint Infection
8%
HIV
8%
Bacterial Arthritis
8%
Lung Tuberculosis
8%
Arthritis
8%
Lactam
8%
Gram Negative Bacterium
8%
Hospital Mortality
8%
Immunosuppressive Agent
8%
Streptococcus
8%
Coagulase Negative Staphylococcus
7%
Hospital Infection
6%
Amphotericin B
6%
Tocilizumab
6%
Prospective Study
6%
Miliary Tuberculosis
6%
Vancomycin
6%
Aspergillus
6%